luid. The Phase III trial evaluating Synvisc-One in hip osteoarthritis did not reach its primary endpoint in 2015. In 2015, the main countries contributing to Synvisc and Synvisc-One sales were the U.S., Mexico, France, Canada, Germany and Brazil. Auvi-Q/Allerject In October 2015, the company announced a voluntary recall for Auvi-Q and Allerject in the U.S. and Canada. The company has decided to return all the U.S. and Canadian rights to Auvi-Q to the developer of Auvi-Q. Consumer Health Care (CHC) In the U.S.: Allegra gelcaps, designed to ease the ingestion of the product. This version of the product is the first extension of the brand since its transition to OTC status in 2011; The pediatric version of Nasacort Allergy 24HR, marketed one year after the transition of the brand to OTC status in 2014; IcyHot SmartRelief for shoulders and knees, a new version of the drug-free pain-relief device, based on Transcutaneous Electrical Nerve Stimulation (TENS) technology, blocking pain signals and stimulating the production of endorphins, the body’s naturally produced pain relievers. The IcyHot SmartRelief brand has been available throughout the U.S. since the fall of 2014; Aspercreme, a lidocain-based cream providing a new, odorless and non-irritant solution for consumers suffering from pain and constantly looking for new means to attenuate it. In France, the launch of a range of OTC pain-relief products, including DolipraneOrodoz 500 mg, an oro-dispersible tablet that might be taken with or without water; DolipraneTabs, a coated tablet masking the relatively bitter taste of paracetamol (500 mg and 1000 mg formulations); DolipraneCaps, an easy-to-swallow capsule containing 1000 mg of paracetamol; and DolipraneLiquiz, an oral suspension in liquid, single-dose stick-packs for children. These new products fill out the pain-relief offering of the company, in which Doliprane plays a central role and covers the needs of patients of all ages, mainly on the French market and in various African countries. Growth in 2015 was also supported by a range of Consumer Health Care products listed below that enable the company to play a major role in the field of digestive health: No Spa (drotaverine hydrochloride) is an abdominal anti-spasmodic, indicated for intestinal spasms, menstrual pain and bladder spasm. No Spa is sold mainly in Russia and Eastern Europe where sales volumes have grown steadily; Enterogermina is a probiotic in the form of a drinkable suspension in 5 ml bottles or capsules containing two billion Bacillus clausii spores. Enterogermina is indicated for the maintenance and restoration of intestinal flora in the treatment of acute or chronic intestinal disorders (in babies and adults). Enterogermina is sold primarily in Europe with strong growth in Latin America, India, Ukraine and Belarus; Essentiale is a plant-based product for the treatment of liver problems. It includes essential phospholipids extracted from highly purified soya and contains a high percentage of phosphatidylcholine, a major component of the cell membrane. Essentiale is used to alleviate symptoms, such as loss of appetite, pressure in the right epigastrium, food-related liver lesions and hepatitis. Essentiale is sold mainly in Russia (no. 1 CHC product in the market), Eastern Europe, various countries in Southeast Asia and China; Maalox is a well-established brand that contains two antacids, aluminum hydroxide and magnesium hydroxide. It is available in various forms, namely tablets, oral suspension and sachets, thus offering consumers a range of suitable solutions. Maalox is available in 55 countries in Europe, Latin America and Asia; Magne B6 is a food supplement containing magnesium and vitamin B6. It has a range of therapeutic indications, including irritability, anxiety, sleep disorders and women’s health issues (premenstrual syndrome and menopausal problems). Magne B6 is available primarily in Europe and Russia; The Lactacyd range covers various intimate feminine-hygiene products. Lactacyd is sold mainly in Brazil and in Asia where the range, improved with several new products, has continued to show stron
sanofi-titr part10%87 (RHPP:EN Paris)
54, Rue La Boétie
Phone: 33 1 53 77 40 00
Fax: 33 1 53 77 42 96www.sanofi.com
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for RHPP.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact SANOFI-TITR PART10%87, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.